{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T16:15:03Z","timestamp":1781885703977,"version":"3.54.5"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,3,13]],"date-time":"2024-03-13T00:00:00Z","timestamp":1710288000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.14283\/jpad.2024.55","type":"journal-article","created":{"date-parts":[[2024,3,6]],"date-time":"2024-03-06T12:43:44Z","timestamp":1709729024000},"page":"992-997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of \u201cTime Saved\u201d"],"prefix":"10.1016","volume":"11","author":[{"given":"Samuel P.","family":"Dickson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kivipelto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Hartmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M.J.","family":"van Hees","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Brownlee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Haaland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.H.","family":"Mallinckrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.B.","family":"Hendrix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2024.55_bib1","doi-asserted-by":"crossref","first-page":"9","DOI":"10.14283\/jpad.2022.102","article-title":"Establishing Clinically Meaningful Change on Outcome Assessments Frequently Used in Trials of Mild Cognitive Impairment Due to Alzheimer's Disease","volume":"10","author":"Lansdall","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.55_bib2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.14283\/jpad.2022.103","article-title":"Editorial: Change on Clinical Trial Outcome Assessments: The Search for Meaningfulness","volume":"10","author":"Cummings","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.55_bib3","doi-asserted-by":"crossref","first-page":"2730","DOI":"10.1002\/alz.12959","article-title":"Expectations and clinical meaningfulness of randomized controlled trials","volume":"19","author":"Petersen","year":"2023","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.55_bib4","doi-asserted-by":"crossref","DOI":"10.1212\/CPJ.0000000000200127","article-title":"Meaningful Clinical Changes in Alzheimer Disease Measured With the iADRS and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings","volume":"13","author":"Wessels","year":"2023","journal-title":"Neurol Clin Pract"},{"key":"10.14283\/jpad.2024.55_bib5","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1002\/sim.9581","article-title":"Progression models for repeated measures: Estimating novel treatment effects in progressive diseases","volume":"41","author":"Raket","year":"2022","journal-title":"Stat Med"},{"key":"10.14283\/jpad.2024.55_bib6","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0006-8993(03)03320-1","article-title":"Dietary fatty acids alter blood pressure, behavior and brain membrane composition of hypertensive rats","volume":"988","author":"de Wilde","year":"2003","journal-title":"Brain Res"},{"key":"10.14283\/jpad.2024.55_bib7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1074-7427(03)00024-8","article-title":"Combined uridine and choline administration improves cognitive deficits in spontaneously hypertensive rats","volume":"80","author":"De Bruin","year":"2003","journal-title":"Neurobiol Learn Mem"},{"key":"10.14283\/jpad.2024.55_bib8","doi-asserted-by":"crossref","first-page":"327","DOI":"10.3233\/JAD-2011-110635","article-title":"Neuroprotective effects of a specific multi-nutrient intervention against Abeta42-induced toxicity in rats","volume":"27","author":"de Wilde","year":"2011","journal-title":"Journal of Alzheimer's disease: JAD"},{"key":"10.14283\/jpad.2024.55_bib9","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3233\/JAD-2012-112039","article-title":"A specific multi-nutrient diet reduces Alzheimer-like pathology in young adult AbetaPPswe\/PS1dE9 mice","volume":"33","author":"Broersen","year":"2013","journal-title":"Journal of Alzheimer's disease: JAD"},{"key":"10.14283\/jpad.2024.55_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075393","article-title":"Effects of specific multi-nutrient enriched diets on cerebral metabolism, cognition and neuropathology in AbetaPPswe-PS1dE9 mice","volume":"8","author":"Jansen","year":"2013","journal-title":"PLoS One"},{"key":"10.14283\/jpad.2024.55_bib11","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.neurobiolaging.2013.09.038","article-title":"Multinutrient diets improve cerebral perfusion and neuroprotection in a murine model of Alzheimer's disease","volume":"35","author":"Zerbi","year":"2014","journal-title":"Neurobiol Aging"},{"key":"10.14283\/jpad.2024.55_bib12","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jnutbio.2013.09.015","article-title":"Special lipid-based diets alleviate cognitive deficits in the APPswe\/PS1dE9 transgenic mouse model of Alzheimer's disease independent of brain amyloid deposition","volume":"25","author":"Koivisto","year":"2014","journal-title":"The Journal of nutritional biochemistry"},{"key":"10.14283\/jpad.2024.55_bib13","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1194\/jlr.R076331","article-title":"Omega-3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi-nutrient dementia prevention","volume":"58","author":"Grimm","year":"2017","journal-title":"J Lipid Res"},{"key":"10.14283\/jpad.2024.55_bib14","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13195-019-0528-6","article-title":"Souvenaid in the management of mild cognitive impairment: an expert consensus opinion","volume":"11","author":"Cummings","year":"2019","journal-title":"Alzheimers Res Ther"},{"key":"10.14283\/jpad.2024.55_bib15","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1016\/S1474-4422(17)30332-0","article-title":"24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial","volume":"16","author":"Soininen","year":"2017","journal-title":"Lancet Neurol"},{"key":"10.14283\/jpad.2024.55_bib16","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/alz.12172","article-title":"36-month LipiDiDiet multinutrient clinical trial in prodromal Alzheimer's disease","volume":"17","author":"Soininen","year":"2021","journal-title":"Alzheimers Dement"},{"key":"10.14283\/jpad.2024.55_bib17","unstructured":"Hogan N, Johnson J, Knowlton N, Hennessey S, Hendrix S, Dickson SP, editors. The Inherent Meaningfulness of a Novel Time Component Test (TCT): Combining Evidence Across Outcomes to Measure the Impact of Treatment on Progression Rate in Degenerative Diseases. JSM Proceedings; 2022; Washington DC."},{"key":"10.14283\/jpad.2024.55_bib18","unstructured":"Hendrix S, Knowlton N, Hogan N, Johnson J, Dickson SP, editors. Identifying Disease-Modifying Treatments in Progressive Diseases Through Delayed Failure Time Models and Delayed Longitudinal Progression Models. JSM Proceedings; 2022; Washington DC."},{"key":"10.14283\/jpad.2024.55_bib19","first-page":"S51","article-title":"P-23: The time component test is inherently meaningful because it combines evidence across outcomes to measure the impact of treatment on progression rate in degenerative diseases","author":"Dickson","year":"2022","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.55_bib20","doi-asserted-by":"crossref","first-page":"595","DOI":"10.14283\/jpad.2023.50","article-title":"\u2018Time Saved' As a Demonstration of Clinical Meaningfulness and Illustrated Using the Donanemab TRAILBLAZER-ALZ Study Findings","volume":"10","author":"Dickson","year":"2023","journal-title":"J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.55_bib21","doi-asserted-by":"crossref","DOI":"10.14283\/jpad.2024.64","article-title":"\u201cTime saved\u201d calculations to improve decision-making in progressive disease studies","author":"Dickson","year":"2024","journal-title":"To appear in J Prev Alzheimers Dis"},{"key":"10.14283\/jpad.2024.55_bib22","series-title":"Quadratic Programming. Numerical Optimization","first-page":"448","author":"Nocedal","year":"2006"},{"key":"10.14283\/jpad.2024.55_bib23","series-title":"Analyzing Longitudinal Clinical Trial Data: A Practical Guide","author":"Mallinckrodt","year":"2017"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000244?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2274580724000244?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T02:07:44Z","timestamp":1737338864000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2274580724000244"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2024,8]]}},"alternative-id":["S2274580724000244"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2024.55","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of Clinical Meaningfulness of Fortasyn Connect in Terms of \u201cTime Saved\u201d","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2024.55","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2024 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}